Back to results
US 2009/0214644 A1Published application
Tranexamic acid formulations with reduced adverse effects
AssigneeXanodyne Pharmaceuticals, Inc.
InventorsRalph A. HEASLEY, Keith A. Moore, Jeffrey S. Greiwe, John W. Facemire, Jason D. Modest
Life of this patent
Estimating the term…
Abstract
Disclosed are delayed release oral tranexamic acid formulations and methods of treatment therewith.
Claims20
A delayed release oral dosage form comprising:
- a core comprising tranexamic acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient;
- and
- a delayed release material coated on the core which provides for the delayed release of the tranexamic acid or pharmaceutically acceptable salt thereof such that the dosage form is suitable for administration on a two or three times a day basis.
A delayed release oral dosage form comprising:
- a matrix core comprising tranexamic acid or a pharmaceutically acceptable salt thereof and a delayed release material which provides for the delayed release of the tranexamic acid or pharmaceutically acceptable salt thereof such that the dosage form is suitable for administration on a two or three times a day basis.
A delayed release oral dosage form comprising:
- a plurality of multiparticulates comprising tranexamic acid or a pharmaceutically acceptable salt thereof, and a delayed release material which provides for the delayed release for the tranexamic acid or pharmaceutically acceptable salt thereof such that the dosage form is suitable for administration on a two or three times a day basis.
Dependencies are inferred from the claim text.